The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, ...
ALS Ltd. has reported its financial results for the first half of fiscal year 2025, highlighting changes in its investment in Nuvisan, moving from a 49% to a 100% consolidated stake. The company’s ...
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter ...
ALS shares hit a record high as earnings growth, dividends, and strong momentum keep investors interested. The post This ASX ...
In a report released today, Niraj Shah from Goldman Sachs maintained a Buy rating on ALS Ltd. (CPBLF – Research Report), with a price target of A$13.60. Niraj Shah has given his Buy rating due to a ...
We increase our fair value estimate for no-moat-rated ALS by 2.5% to AUD 8.60, driven largely by the time value of money. The materials testing specialist also reported stronger-than-expected ...
In a report released today, Joseph House from Bell Potter maintained a Buy rating on ALS Ltd. (CPBLF – Research Report), with a price target of A$18.00. See what stocks are receiving Strong Buy ...
We upgrade ALS Limited’s moat rating to narrow from no moat, and accordingly, our fair value estimate rises by 12% to AUD 10.20 per share. We estimate returns on invested capital, including goodwill, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results